Roche aims to prove life-saving benefits of aleglitazar

pharmafile | June 10, 2009 | News story | Research and Development |  Roche, diabetes 

Related Content

First 90 days of antipsychotic treatment linked to rapid metabolic changes

The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood …

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in …

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

The Gateway to Local Adoption Series

Latest content